What were Merck's primary drivers of sales growth in 2022?

Merck's sales growth in 2022 was primarily driven by strong performance in its oncology franchise, particularly Keytruda, which saw a 22% increase in sales. Additionally, significant sales from Lagevrio, an antiviral medication for COVID-19, contributed substantially to the overall revenue growth. The vaccine segment, especially Gardasil/Gardasil 9, also showed robust growth.

What is the outlook for Lagevrio sales in 2023?

Merck anticipates a significant decline in Lagevrio sales for 2023, projecting approximately $1.0 billion in sales compared to $5.7 billion in 2022. This expected decrease is attributed to the waning impact of the COVID-19 pandemic and a reduced demand for antiviral treatments.

How is Merck managing pricing pressures and regulatory changes in the pharmaceutical industry?

Merck is actively navigating pricing pressures through ongoing business development, including strategic collaborations and acquisitions, to strengthen its product pipeline. The company also engages in public policy advocacy to demonstrate the value of its medicines and address regulatory changes, such as those introduced by the Inflation Reduction Act, while mitigating potential negative impacts.

What are the key risks facing Merck according to the 10-K filing?

Key risks identified include dependence on patent protection, the potential loss of market exclusivity for key products, intense competition from generic and branded products, pricing pressures globally, the success of its R&D pipeline, and the potential impact of global economic conditions and regulatory changes. The company also highlights risks associated with its significant global operations and potential cybersecurity threats.

What is Merck's strategy for future growth?

Merck's growth strategy centers on a science-led approach, focusing on investing in its internal pipeline while actively pursuing value-enhancing business development opportunities through collaborations, licensing agreements, and acquisitions. The company aims to address significant unmet medical needs and maximize the value of its approved medicines through new indications and formulations, alongside a continued focus on its Animal Health business.

MRK 10-K FY2022 Annual Report — Revenue, Net Income, EPS

Summary

Merck & Co., Inc. reported robust performance in 2022, with total sales reaching $59.3 billion, a 22% increase year-over-year, driven significantly by its oncology franchise, particularly Keytruda, and strong sales from Lagevrio (a COVID-19 treatment). The company continues to focus on strategic business development, announcing several collaborations and acquisitions to bolster its pipeline in key therapeutic areas like oncology and infectious diseases. While sales growth was strong, investors should note the expected significant decline in Lagevrio sales for 2023, as the COVID-19 pandemic's impact wanes. Merck also highlighted its commitment to returning value to shareholders through dividends and share repurchases, alongside ongoing investments in research and development to drive future growth. Key risks and challenges identified include the ongoing pricing pressures in the healthcare industry, competition from generic products, and potential impacts from global economic conditions and regulatory changes, such as the Inflation Reduction Act. The company's patent portfolio remains crucial, with ongoing efforts to defend intellectual property rights against challenges.

Financial Highlights

58 data points

Beta

Revenue

$59.28B

0.7% Gross Margin

Net Income

$14.52B

0.2% Net Margin

EPS (Diluted)

$5.71

Total Assets

$109.16B

Cash & Equivalents

$12.69B

Free Cash Flow

$14.71B

Financial Statements

Beta

Revenue	$59.28B
Cost of Revenue	$17.41B
Gross Profit	$41.87B
R&D Expenses	$13.55B
SG&A Expenses	$10.04B
Operating Income	$14.52B
Interest Expense	$962.00M
Net Income	$14.52B
EPS (Basic)	$5.73
EPS (Diluted)	$5.71
Shares Outstanding (Basic)	2.53B
Shares Outstanding (Diluted)	2.54B

Key Highlights

1Total sales increased by 22% to $59.3 billion in 2022, primarily driven by strong performance in oncology (Keytruda) and significant contributions from Lagevrio.
2Keytruda demonstrated robust growth, with sales up 22% year-over-year, supported by numerous new indications and approvals globally.
3Lagevrio sales contributed significantly to 2022 revenue ($5.7 billion), though sales are expected to decline sharply to approximately $1.0 billion in 2023.
4Merck actively pursued business development, including collaborations with Moderna and Orna Therapeutics, and the acquisition of Imago BioSciences, to strengthen its pipeline and future growth prospects.
5The company continued to invest heavily in R&D, with expenses increasing by 11% to $13.5 billion in 2022, focusing on pipeline advancement across various therapeutic areas.
6The Animal Health segment remained stable, with sales largely consistent year-over-year, showing resilience in that market.
7Merck continues to prioritize capital allocation towards business investments, dividends, and share repurchases, signaling confidence in its ongoing operational performance and future outlook.

Merck & Co., Inc. Annual Report, Year Ended Dec 31, 2022

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions